Western blot:A suitable range of concentrations of this antibody for WB detection is 2-10 µg/ml.
IHC: A suitable range of concentrations of this antibody for IHC is 2-10 µg/ml.
Immunohistochemical analysis of IGF-I expression in NZ rabbit knee joint tissue.
Cat# RPA01343 was used as primary antibody, dilution 1:200.
Source:
Polyclonal IGF-I antibody was produced from sera of rabbits immunized with synthetic protein containing IGF-1 antigenic determinants.
Species reactivity:
Human,Mouse,Rat
Purification:
Serum IgG fraction was purified by Protein A affinity chromatography.
Presentation:
Lyophilized from sterile filtered PBS solution at a concentration of 1mg/ml.
Reconstitution:
A quick spin of the vial followed by reconstitution in distilled water. This solution can then be diluted into other buffers
Storage:
The lyophilized antibody is stable for at least 1 year from date of receipt at -20° C.
Upon reconstitution, this antibody can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months without detectable loss of activity.
Avoid repeated freeze/thaw cycles.
Usage:
This antibody product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
IGF-I
Insulin-like growth factor
I, also known as somatomedin
C, is the dominant effector
of growth hormone and is
structurally homologous to
proinsulin. Human IGF-I is
synthesized as two precursor
isoforms with N- and
alternate C- terminal
propeptides (1). These
isoforms are differentially
expressed by various tissues
(1). The 7.6 kDa mature IGF-
I is identical between
isoforms and is generated by
proteolytic removal of the
N- and C- terminal regions.
Mature human IGF-I shares
94% and 96% aa sequence
identity with mouse and rat
IGF-I, respectively (2), and
exhibits cross-species
activity. It shares 64% aa
sequence identity with
mature human IGF-II.
Circulating IGF-I is
produced by hepatocytes,
while local IGF-I is
produced by many other
tissues in which it has
paracrine effects.
Related Publications:
mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor -mediated control of insulin-like growth factor (igf) i receptor sensitivity to ambient igf, leading to phosphatidylinositol 3-kinase/akt-dependent wnt/lrp5 receptor-independent activation of β-catenin signaling
J. Biol. Chem.,
Mar 2010;
285:
8743 - 8758.
IGF-I lucidity...the murky waters begin to clear?
J Appl Physiol,
Mar 2010;
10.1152/japplphysiol.00252.2010.
a significant decline in IGF-I may predispose young africans to subsequent cardiometabolic vulnerability
J. Clin. Endocrinol. Metab.,
Mar 2010;
10.1210/jc.2009-2329.
insulin-like growth factor-1 (IGF-I) stimulated insulin receptor substrate-1 negatively regulates src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells
J. Biol. Chem.,
Mar 2010;
10.1074/jbc.M109.092270.
deletion of the IGF-I gene: suppressive effects on adult leydig cell development
J Androl,
Mar 2010;
10.2164/jandrol.109.008680.
